Page last updated: 2024-11-11

z-val-ala-asp(ome)-fluoromethylketone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

z-Val-Ala-Asp(Ome)-fluoromethylketone: confuse with Z-VAD-FMK [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Z-Val-Ala-Asp(OMe)-CH2F : A tripeptide consisting of Z-Val-Ala-Asp(OMe) in which the C-terminal OH group has been replaced by a fluoromethyl group. An irreversible pan-caspase inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5497174
CHEMBL ID1213366
CHEBI ID137045
SCHEMBL ID15012737
MeSH IDM0452357

Synonyms (87)

Synonym
CBIOL_001923
z-vad(ome)-fmk
CHEMBL1213366
BIO2_000951
BIO2_000471 ,
BIO1_000698
BIO1_000209
BIO1_001187
PROBES1_000501
BSPBIO_001262
IDI1_002226
187389-52-2
l-alaninamide, n-[(phenylmethoxy)carbonyl]-l-valyl-n-[(1s)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]- (9ci)
l-alaninamide, n-[(phenylmethoxy)carbonyl]-l-valyl-n-[(1s)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-
5-bromo-2 -deoxyuridine
z-vad (ome)-fmk
NCGC00163487-01
KBIO3_001063
KBIO3_001064
KBIOGR_000602
KBIO2_000602
KBIO2_003170
KBIOSS_000602
KBIO2_005738
NCGC00163487-02
z-l-val-l-ala-l-asp(ome)-ch2f
z-val-ala-asp(ome)-ch2f
z-val-ala-asp(ome)-fluoromethyl ketone
n-[(benzyloxy)carbonyl]-l-valyl-n-[(3s)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]-l-alaninamide
z-val-ala-asp(ome)-fmk
pan-caspase inhibitor
CHEBI:137045
HMS1990P03
HMS1792P03
HMS1362P03
methyl (3s)-5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoyl]amino]-4-oxopentanoate
methyl 5-fluoro-3-[2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]propanoylamino]-4-oxopentanoate
methyl (3s)-5-fluoro-3-[[(2s)-2-[[(2s)-3-methyl-2-phenylmethoxycarbonylamino-butanoyl]amino]propanoyl]amino]-4-oxo-pentanoate
CCG-207882
CS-3153
HY-16658
c22h30fn3o7
SCHEMBL15012737
benzyloxycarbonyl-val-ala-asp(ome)-fluoromethylketone
DTXSID40420586
HB1285
z-vad-(ome)-fmk
HB1319
methyl (5s,8s,11s)-11-(2-fluoroacetyl)-5-isopropyl-8-methyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazatridecan-13-oate
AKOS024456966
HMS3403P03
mfcd02684037
methyl (3s)-3-[(2s)-2-[(2s)-2-{[(benzyloxy)carbonyl]amino}-3-methylbutanamido]propanamido]-5-fluoro-4-oxopentanoate
AS-74918
J-012061
SW219162-1
caspase inhibitor i - cas 187389-52-2
caspase-1 inhibitor z-val-ala-dl-asp-fluoromethylketone
S7023
cbz-val-ala-asp(ome)-fluoromethylketone
z-val-ala-asp(och3)-fluoromethylketone
n-benzyloxycarbonyl-val-ala-asp(o-me) fluoromethyl ketone
n-benzyloxycarbonyl-val-ala-asp(ome) fluoromethyl ketone
benzyloxycarbonyl-val-ala-asp(ome)fluoromethyl ketone
z-vad(ome)-fmk; z-val-ala-asp(ome)-fmk
n-benzyloxycarbonyl-val-ala-asp(o-methyl)-fluoromethylketone
n-benzyloxycarbonyl-val-ala-asp(o-methyl) fluoromethyl ketone
benzyloxycarbonyl-val-ala-asp(ome)-fluoromethyl ketone
benzyloxycarbonyl-val-ala-asp(ome) fluoromethyl ketone
z-val-ala-asp(ome)-fluoromethyl-ketone
z-val-ala-asp(o-methyl)-fluoromethylketone
benzyloxycarbonyl-val-ala-asp(o-methyl)-fluoromethylketone
z-val-ala-asp(och3)-ch2f
z-val-ala-asp(och3)-fluoromethyl ketone
z-val-ala-asp(ome) fluoromethylketone
n-benzyloxycarbonyl-val-ala-asp(ome)fluoromethylketone
z-val-ala-asp(ome)-fluoromethylketone
n-benzyloxycarbonyl-val-ala-asp(ome)-fluoromethylketone
n-benzyloxycarbonyl-val-ala-asp(o-methyl)-fluoromethyl ketone
cbz-val-ala-asp(ome)-fluoromethyl ketone
n-benzyloxycarbonyl-val-ala-asp(ome)fluoromethyl ketone
EX-A2192
n-benzyloxycarbonyl-val-ala-asp(ome) fluoromethylketone
benzyloxycarbonyl-val-ala-asp(o-me) fluoromethyl ketone
zvad-fmk
A857181
(5s,8s,11s)-methyl 11-(2-fluoroacetyl)-5-isopropyl-8-methyl-3,6,9-trioxo-1-phenyl-2-oxa-4,7,10-triazatridecan-13-oate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
protease inhibitorA compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
carbamate esterAny ester of carbamic acid or its N-substituted derivatives.
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Calpain-9Homo sapiens (human)IC50 (µMol)100.00001.61003.97609.8800AID1620950
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
digestionCalpain-9Homo sapiens (human)
proteolysisCalpain-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
calcium ion bindingCalpain-9Homo sapiens (human)
calcium-dependent cysteine-type endopeptidase activityCalpain-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
cellular_componentCalpain-9Homo sapiens (human)
cytoplasmCalpain-9Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1175449Antiapoptotic activity in camptothecin-induced human Jurkat cells assessed as apoptotic cells at 10 uM after 2 hrs using Annexin V-FITC and 7-AAD by flow cytometry relative to control2014Bioorganic & medicinal chemistry, Dec-15, Volume: 22, Issue:24
Synthesis and evaluation of N-acyl-substituted 1,2-benzisothiazol-3-one derivatives as caspase-3 inhibitors.
AID628172Induction of apoptosis in human Jurkat cells assessed as hypodyploid cells at 50 nM after 48 hrs by annexin-V FITC/7-ADD staining-based flow cytometric analysis in presence of 50 uM Z-VAD-fmk pan-caspase inhibitor2011Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20
Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID497859Inhibition of cellular necroptosis in TNFalpha treated FADD and RIP1 deficient human Jurkat cells at 30 uM2008Nature chemical biology, May, Volume: 4, Issue:5
Identification of RIP1 kinase as a specific cellular target of necrostatins.
AID608035Suppression of staurosporine-induced apoptosis in human HeLa cells assessed as reduction in DNA fragmentation at 100 uM after 24 hrs by propidium iodide-staining based FACS assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID608034Suppression of camptothecin-induced apoptosis in human HeLa cells assessed as reduction in DNA fragmentation at 100 uM after 24 hrs by propidium iodide-staining based FACS assay2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's23 (69.70)29.6817
2010's8 (24.24)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.85 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]